Skyrizi vs Rinvoq
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| CA Skyrizi | CA Rinvoq | |
|---|---|---|
| Generic name | risankizumab | upadacitinib |
| Drug class | IL-23 Inhibitor (Biologic) | JAK Inhibitor |
| Treats | Plaque psoriasis, psoriatic arthritis, Crohn's disease | Rheumatoid arthritis, psoriatic arthritis, eczema |
| Category | Autoimmune | Autoimmune |
| Manufacturer | AbbVie | AbbVie |
| Year approved | 2019 | 2019 |
| FDA warning | Moderate warnings | Black box warning |
| Est. TV ad spend | $48M | $38M |
| Common side effects | Respiratory infections, Headache, Fatigue, Injection site reactions | Serious infections, Blood clots, Cardiovascular events, Cancer risk |
Frequently asked questions
Is Skyrizi or Rinvoq better?
Neither is universally "better." Skyrizi (risankizumab) and Rinvoq (upadacitinib) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Skyrizi and Rinvoq?
Skyrizi is a IL-23 Inhibitor (Biologic) made by AbbVie, while Rinvoq is a JAK Inhibitor made by AbbVie. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Skyrizi has the larger estimated TV advertising budget of the two.